PALI — PALISADE BIO, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1357459 ·
Last close
$1.45
Market Cap
$252.69M
52W High
$2.86
52W Low
$0.79
ADV30
2,759,403
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 500,000 | — | -11,698,000 | -10,574,000 | 127,315,000 | 125,172,000 | 5,567,000 |
| Mar 2026 | 0 | — | -10,748,000 | -9,600,000 | 133,315,000 | 132,628,000 | 5,953,000 |
| Dec 2025 | 0 | — | -9,981,000 | -8,899,000 | 134,344,000 | 133,385,000 | 4,964,000 |
| Sep 2025 | 0 | — | -2,922,000 | -2,868,000 | 6,973,000 | 5,227,000 | 3,761,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,404,000
Investing CF
$0
Financing CF
$137,831,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.48
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-162,325,000
Inventory
—
Receivables
$9,000
ST Investments
—
EBIT TTM
$-24,141,000
Pretax Income TTM
$-24,151,000
Interest Exp TTM
$10,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$500,000
EBITDA
$-35,346,500
Free Cash Flow
$-8,654,125
Enterprise Value
$233,827,344
Total Cash
$125,172,000
Total Debt
$0
Shares Out
174,270,558
Trailing EPS
$0.65
Book Value
$0.70
ROE
-51.4%
ROA
-33.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -18,056,000 | -16,781,000 | 134,344,000 | 4,964,000 | 129,380,000 | -10,847,000 |
| Dec 2024 | 0 | -14,859,000 | -14,438,000 | 10,880,000 | 3,388,000 | 7,492,000 | -12,193,000 |
| Dec 2023 | 250,000 | -12,845,000 | -12,300,000 | 14,052,000 | 2,739,000 | 11,313,000 | -11,133,000 |
| Dec 2022 | 0 | -15,311,000 | -14,260,000 | 15,763,000 | 3,284,000 | 12,479,000 | -13,360,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-2,230,000
OpCashFlow TTM
$0
Assets (Latest)
$134,344,000
Forward EPS
$-0.28
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc. | $260.49M | $1.03 | — |
| STRO | SUTRO BIOPHARMA, INC. | $264.97M | $15.98 | — |
| LXEO | Lexeo Therapeutics, Inc. | $271.57M | $3.31 | — |
| IVVD | Invivyd, Inc. | $275.30M | $0.93 | — |
| FATE | FATE THERAPEUTICS INC | $281.58M | $2.35 | — |
News headlines (Yahoo Finance, 1h cache)
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
2026-09-28 12:50 · Yahoo
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
2026-09-27 17:01 · Yahoo
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
2026-09-22 12:35 · Yahoo
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-21 13:00 · Yahoo
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
2026-07-27 11:30 · Yahoo
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
2026-06-29 17:49 · Yahoo
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
2026-06-11 12:45 · Yahoo
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
2026-05-27 13:00 · Yahoo
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
2026-05-18 04:49 · Yahoo
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
2026-09-23 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.